Clinical Trial: Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

U.S., Dec. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07300241) titled 'Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma' on Dec. 10.

Brief Summary: The NEO-811-101 study is an open-label, first-in-human, Phase 1/2 dose escalation and expansion study of NEO-811 for subjects with locally advanced or metastatic non-resectable clear cell renal cell carcinoma. The study will test NEO-811 initially as a monotherapy.

Study Start Date: Dec., 2025

Study Type: INTERVENTIONAL

Condition: Clear Cell Renal Cell Carcinoma Renal Cell Carcinoma RCC Clear Cell Renal Cell Carcinoma Metastatic ccRCC VHL-Associated Clear Cell Renal Cell...